Poseida Therapeutics Stock Cash And Equivalents
Poseida Therapeutics fundamentals help investors to digest information that contributes to Poseida Therapeutics' financial success or failures. It also enables traders to predict the movement of Poseida Stock. The fundamental analysis module provides a way to measure Poseida Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Poseida Therapeutics stock.
Poseida |
Poseida Therapeutics Company Cash And Equivalents Analysis
Poseida Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Poseida Therapeutics Cash And Equivalents | 142.56 M |
Most of Poseida Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Poseida Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Poseida Therapeutics has 142.56 M in Cash And Equivalents. This is 82.63% lower than that of the Biotechnology sector and 68.12% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 94.72% higher than that of the company.
Poseida Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Poseida Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Poseida Therapeutics could also be used in its relative valuation, which is a method of valuing Poseida Therapeutics by comparing valuation metrics of similar companies.Poseida Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Poseida Fundamentals
| Return On Equity | -0.58 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.40) % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 777.81 M | |||
| Shares Outstanding | 97.47 M | |||
| Shares Owned By Insiders | 27.64 % | |||
| Shares Owned By Institutions | 58.44 % | |||
| Number Of Shares Shorted | 3.59 M | |||
| Price To Earning | 214.00 X | |||
| Price To Book | 10.62 X | |||
| Price To Sales | 6.14 X | |||
| Revenue | 64.7 M | |||
| Gross Profit | (21.57 M) | |||
| EBITDA | (109.04 M) | |||
| Net Income | (123.43 M) | |||
| Cash And Equivalents | 142.56 M | |||
| Cash Per Share | 1.66 X | |||
| Total Debt | 85.42 M | |||
| Debt To Equity | 1.39 % | |||
| Current Ratio | 3.69 X | |||
| Book Value Per Share | 0.90 X | |||
| Cash Flow From Operations | (92.17 M) | |||
| Short Ratio | 1.49 X | |||
| Earnings Per Share | (0.63) X | |||
| Price To Earnings To Growth | (0.63) X | |||
| Target Price | 9.5 | |||
| Number Of Employees | 350 | |||
| Beta | 0.54 | |||
| Market Capitalization | 925.93 M | |||
| Total Asset | 273.88 M | |||
| Retained Earnings | (594.29 M) | |||
| Working Capital | 155.16 M | |||
| Current Asset | 10.59 M | |||
| Current Liabilities | 5.1 M | |||
| Net Asset | 273.88 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Poseida Stock
If you are still planning to invest in Poseida Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poseida Therapeutics' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |